Opendata, web and dolomites

PRECIOUS SIGNED

PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "PRECIOUS" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAIR MEDISCH CENTRUM UTRECHT 

Organization address
address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX
website: www.umcutrecht.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.precious-trial.eu
 Twitter https://twitter.com/precious_trial
 Total cost 5˙994˙000 €
 EC max contribution 5˙994˙000 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2014-two-stage
 Funding Scheme RIA
 Starting year 2015
 Duration (year-month-day) from 2015-06-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) coordinator 1˙592˙763.00
2    ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK FR (PARIS) participant 539˙595.00
3    OSLO UNIVERSITETSSYKEHUS HF NO (OSLO) participant 476˙625.00
4    CTC NORTH GMBH & CO KG DE (HAMBURG) participant 384˙400.00
5    UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF DE (HAMBURG) participant 372˙250.00
6    THE UNIVERSITY OF EDINBURGH UK (EDINBURGH) participant 362˙653.00
7    ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) participant 323˙165.00
8    ARTTIC FR (PARIS) participant 317˙983.00
9    UNIVERSITY OF GLASGOW UK (GLASGOW) participant 263˙726.00
10    DEBRECENI EGYETEM HU (DEBRECEN) participant 257˙600.00
11    AZIENDA SOCIO SANITARIA TERRITORIALE DI MANTOVA(ASST DI MANTOVA) IT (MANTOVA) participant 250˙360.00
12    PANEPISTIMIO THESSALIAS EL (VOLOS) participant 236˙350.00
13    INSTYTUT PSYCHIATRII I NEUROLOGII PL (WARSZAWA) participant 230˙100.00
14    SIHTASUTUS TARTU ULIKOOLI KLIINIKUM EE (TARTU) participant 121˙725.00
15    THE UNIVERSITY OF NOTTINGHAM UK (NOTTINGHAM) participant 114˙597.00
16    GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG DE (MUENCHEN) participant 82˙016.00
17    STROKE ALLIANCE FOR EUROPE BE (BRUSSELS) participant 45˙025.00
18    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 23˙065.00
19    AZIENDA OSPEDALIERA CARLO POMA IT (MANTUA) participant 0.00

Map

 Project objective

Every year, 1.3 million Europeans have a stroke and one million ultimately die of stroke. One third of stroke patients remain dependent on the help of others. The annual costs for stroke care in Europe are estimated at € 64.1 billion. Stroke incidence increases almost exponentially with age, and the personal, societal, and economic burden of stroke is therefore largely driven by its frequent occurrence in the elderly. The elderly have been strongly underrepresented in previous stroke trials and treatment guidelines have no recommendations specific to this important group. Elderly patients are at the highest risk of complications after stroke, such as infections, fever, and dysphagia. These complications are strongly and independently associated with a higher risk of death or dependency. We will perform a pragmatic, randomised, open clinical trial with blinded outcome assessment in 3800 patients with acute stroke aged 66 years or older, to assess whether pharmacological prevention of infections and fever, and early management of dysphagia, will reduce the risk of death, poor functional outcome, and poor quality of life, and lead to reductions in the costs of stroke care throughout Europe. Patients will be randomised using a factorial design to preventive treatment for 4 days with ceftriaxone, paracetamol, and/or metoclopramide, or to ‘standard care’ alone. The primary outcome is functional outcome at 3 months, assessed with the modified Rankin Scale (mRS), and analysed with ordinal logistic regression. The study will have 90% power to detect a statistically significant shift towards a favourable outcome, assuming a 5% absolute increase in the proportion of patients with a good outcome (mRS 0 to 2) in the intervention group, compared with controls. This simple, safe, and generally available treatment strategy has the potential to lead to an annual reduction of over 25 000 elderly Europeans being dead or dependent as a result of stroke, at very low costs.

 Deliverables

List of deliverables.
Initial dissemination report Documents, reports 2020-01-24 09:03:58
Dissemination plan Documents, reports 2020-01-24 09:03:58
Launch of website and social media accounts Websites, patent fillings, videos etc. 2020-01-24 09:03:58

Take a look to the deliverables list in detail:  detailed list of PRECIOUS deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Bart van der Worp, Bart van der Worp
Prevention of complications to Improve outcome in elderly patients with acute stroke - A randomised clinical trial
published pages: , ISSN: 2396-9881, DOI: 10.1186/ISRCTN82217627
European Stroke Journal 2020-01-24

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PRECIOUS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PRECIOUS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More